Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsLinezolid600mg IV/PO Q12HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
337304.7-6.46.1-8.4300.6337-13032-37 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Brier M, Stalker D, Aronoff G et al. Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction. Antimicrobial agents and chemotherapy 2003; 47(9), 7-13.
  • Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clinical pharmacokinetics 2010; 49(7), 439-47.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Fiaccadori E, Maggiore U, Rotelli C et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2006; 21(5), 1402-6.
  • Fiaccadori E, Maggiore U, Rotelli C et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Critical Care Medicine 2004; 32(12), 2437-2442.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Stalker D, Jungbluth G. Clinical Pharmacokinetics of Linezolid, a Noval Oxazolidinone Antibacterial. Clinical pharmacokinetics 2003; 42(13), 1129-40.
  • Tsuji Y, Hiraki Y, Mizoguchi A et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. Journal of infection and chemotherapy (official journal of the Japan Society of Chemotherapy) 2008; 14(2), 156-60